GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » BioInvent International AB (OSTO:BINV) » Definitions » Total Current Liabilities

BioInvent International AB (OSTO:BINV) Total Current Liabilities : kr87.05 Mil (As of Mar. 2025)


View and export this data going back to 2001. Start your Free Trial

What is BioInvent International AB Total Current Liabilities?

Total current liabilities includes Accounts Payable & Accrued Expense, Short-Term Debt & Capital Lease Obligation, Other Current Liabilities, and Current Deferred Liabilities. BioInvent International AB's total current liabilities for the quarter that ended in Mar. 2025 was kr87.05


BioInvent International AB Total Current Liabilities Historical Data

The historical data trend for BioInvent International AB's Total Current Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

BioInvent International AB Total Current Liabilities Chart

BioInvent International AB Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Total Current Liabilities
Get a 7-Day Free Trial Premium Member Only Premium Member Only 53.51 58.79 87.32 75.92 95.21

BioInvent International AB Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Total Current Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 83.52 91.08 76.07 95.21 87.05

BioInvent International AB Total Current Liabilities Calculation

Total Current Liabilities is the total amount of liabilities that the company needs to pay over the next 12 months.

BioInvent International AB's Total Current Liabilities for the fiscal year that ended in Dec. 2024 is calculated as

Total Current Liabilities=Accounts Payable & Accrued Expense+Short-Term Debt & Capital Lease Obligation
=49.095+9.198
+Other Current Liabilities+Current Deferred Liabilities
=36.913+0
=95.21

BioInvent International AB's Total Current Liabilities for the quarter that ended in Mar. 2025 is calculated as

Total Current Liabilities=Accounts Payable & Accrued Expense+Short-Term Debt & Capital Lease Obligation
=0+9.164
+Other Current Liabilities+Current Deferred Liabilities
=77.881+0
=87.05

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

The increase of Total Current Liabilities of a company is not necessarily a bad thing. This may conserve the company's cash and contribute positively to cash flow.

Total Current Liabilities is linked to Total Current Assets through the Current Ratio and Working Capital. The Current Ratio is equal to dividing total current assets by total current liabilities. It is frequently used as an indicator of a company's liquidity, its ability to meet short-term obligations. Net working capital is calculated as Total Current Assets minus Total Current Liabilities.


Be Aware

Stay away from companies that roll over the debt e.g. Bear Stearns

When investing in financial institutions, Buffett shies from those who are bigger borrowers of short term than long term debt.

His favorite Wells Fargo has 57 cents short term debt for every dollar of long term.

Aggressive banks (like Bank of America) has $2.09 short term for every dollar long term


BioInvent International AB Total Current Liabilities Related Terms

Thank you for viewing the detailed overview of BioInvent International AB's Total Current Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.


BioInvent International AB Business Description

Traded in Other Exchanges
Address
Ideongatan 1, Lund, SWE, SE-223 70
BioInvent International AB is a clinical-stage biotech company. It discovers and develops novel and first-in-class immuno-modulatory antibodies for cancer therapy, with currently four drug candidates in five ongoing clinical programs in Phase 1/2 trials for the treatment of hematological cancer and solid tumors, respectively. The company's validated, proprietary F.I.R.S.T technology platform identifies both targets and the antibodies that bind to them, generating many new drug candidates to fuel the company's clinical development pipeline and providing licensing and partnering opportunities. The company's pipeline portfolio comprises BI-1206, an antagonistic blocking antibody for the treatment of non-Hodgkin's lymphoma, and BI-1808 and BI-1910 (anti-TNFR2) for solid cancers.

BioInvent International AB Headlines

No Headlines